All In Biotech

Drug Trial Radar · NCT01098110

6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)

A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)

Last checked: Nov 20, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

532

Actual

Start

May 25, 2010

Primary completion

Apr 14, 2014

Study completion Apr 14, 2014

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Apr 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, parallel-group, double-blind, fixed dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in participants with an acute exacerbation of schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • Asenapine 5 mgDrug

    Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.

  • Asenapine 10 mgDrug

    Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.

  • PlaceboDrug

    A matching placebo of asenapine sublingual tablet not containing asenapine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.Time frame: Baseline and Day 42

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.